title: Enhanced therapeutic effect of APAVAC immunotherapy in combination with dose-intense chemotherapy in dogs with advanced indolent B-cell lymphoma.
abstract: The aim of this non-randomized controlled trial was to compare time to progression (TTP), lymphoma-specific survival (LSS), and safety of an autologous vaccine (consisting of hydroxyapatite ceramic powder and Heat Shock Proteins purified from the dogs' tumors, HSPPCs-HA) plus chemotherapy versus chemotherapy alone in dogs with newly diagnosed, clinically advanced, histologically confirmed, multicentric indolent B-cell lymphoma. The vaccine was prepared from dogs' resected lymph nodes and administered as an intradermal injection. Forty-five client-owned dogs were enrolled: 20 dogs were treated with dose-intense chemotherapy, and 25 received concurrent immunotherapy. Both treatment arms were well tolerated, with no exacerbated toxicity in dogs also receiving the vaccine. TTP was significantly longer for dogs treated with chemo-immunotherapy versus those receiving chemotherapy only (median, 209 versus 85 days, respectively, P=0.015). LSS was not significantly different between groups: dogs treated with chemo-immunotherapy had a median survival of 349 days, and those treated with chemotherapy only had a median survival of 200 days (P=0.173). Among vaccinated dogs, those mounting an immune response had a significantly longer TTP and LSS than those with no detectable response (P=0.012 and P=0.003, respectively). Collectively these results demonstrate that vaccination with HSPPCs-HA may produce clinical benefits with no increased toxicity, thereby providing a strategy for enhancing chemotherapy in dogs with advanced indolent lymphoma.
authors: Centro Oncologico Veterinario, Sasso Marconi, BO, Italy. Electronic address: marconato@centroncologicovet.it.
authors: L
authors: L
authors: Marconato
authors: Department of Veterinary Sciences and Public Health, University of Milan, Milan, Italy.
authors: D
authors: D
authors: Stefanello
authors: Department of Veterinary Medical Sciences, University of Bologna, Bologna, Italy.
authors: S
authors: S
authors: Sabattini
authors: Department of Veterinary Sciences and Public Health, University of Milan, Milan, Italy.
authors: S
authors: S
authors: Comazzi
authors: Department of Veterinary Sciences, University of Turin, Turin, Italy.
authors: F
authors: F
authors: Riondato
authors: Centro Oncologico Veterinario, Sasso Marconi, BO, Italy.
authors: P
authors: P
authors: Laganga
authors: Urodelia, St Lys, France.
authors: P
authors: P
authors: Frayssinet
authors: Centro Oncologico Veterinario, Sasso Marconi, BO, Italy.
authors: S
authors: S
authors: Pizzoni
authors: Urodelia, St Lys, France.
authors: N
authors: N
authors: Rouquet
authors: Department of Comparative Biomedicine and Food Science, University of Padova, Agripolis Legnaro, Italy.
authors: L
authors: L
authors: Aresu
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000009:adverse effects; D004285:Dogs; D004358:Drug Therapy / Q000379:methods*; D004359:Drug Therapy, Combination / Q000379:methods; D005260:Female; D007167:Immunotherapy / Q000009:adverse effects / Q000379:methods*; D007271:Injections, Intradermal; D016393:Lymphoma, B-Cell / Q000401:mortality / Q000628:therapy / Q000662:veterinary*; D008297:Male; D011446:Prospective Studies; D016019:Survival Analysis; D045506:Therapeutic Uses; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D019496:Cancer Vaccines; D045506:Therapeutic Uses
keywords: Dog; Heat shock proteins; Hydroxyapatite; Immunotherapy; Indolent lymphoma